Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
NEWPORT BEACH, Calif. - Evolus, Inc. (NASDAQ: EOLS), a company specializing in performance beauty products with a market capitalization of $632.5 million, announced the resignation of its Chief Financial Officer, Sandra Beaver, who will leave the company on June 13, 2025. Beaver is set to join a private mental health and wellness technology firm in the same capacity. Her departure is not due to any disputes or disagreements with Evolus’ operational or financial practices. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.34, indicating robust financial stability.
David Moatazedi, President and CEO of Evolus, expressed gratitude for Beaver’s contributions, highlighting her role in the company’s growth and her impact on its financial and strategic positioning. He also noted the company’s recent achievements, including the launch of a second product line and record revenues, which have set the stage for profitability. The company has demonstrated strong growth momentum, with revenue increasing by 25.38% over the last twelve months to $275.46 million. InvestingPro subscribers can access additional insights through exclusive ProTips and comprehensive financial analysis.
Beaver, reflecting on her tenure, praised her finance team and expressed confidence in their ability to continue supporting Evolus’ objectives. She believes the company is well-positioned for future success.
Evolus is now actively searching for Beaver’s successor and has assured stakeholders that in the interim, their experienced finance team will manage the transition smoothly, maintaining the company’s accounting, finance, and investor relations functions.
Evolus, known for its flagship products Jeuveau® and Evolysse™, aims to redefine the aesthetic injectable market with its customer-centric approach and digital platform. The company’s forward-looking statements indicate a focus on financial health and the pursuit of profitability, amidst the uncertainties inherent in product launches and market dynamics. Analyst targets range from $20 to $27 per share, suggesting potential upside, though the company is currently trading near its InvestingPro Fair Value. Detailed analysis and growth projections are available in the comprehensive Pro Research Report, one of 1,400+ expert analyses available to subscribers.
This news is based on a press release statement from Evolus, Inc.
In other recent news, Evolus Inc. reported its Q1 2025 financial results, revealing a larger-than-expected loss with an earnings per share (EPS) of -$0.30, missing the forecast of -$0.09. Despite this, the company’s revenue grew by 15.5% year-over-year to $68.5 million, though it fell short of the $72.51 million forecast. Evolus reaffirmed its full-year revenue guidance of $345-$355 million and is targeting $700 million in net revenue by 2028. The company highlighted the successful launch of Evolisse, a new hyaluronic acid gel expected to contribute 8-10% of total revenue in 2025. Additionally, Evolus announced the publication of a study demonstrating that its Evolysse™ Form and Evolysse™ Smooth products outperformed a leading HA gel in a clinical trial. The company has also received EU Medical Device Regulation approval for four HA gels under the brand name Estyme®, with a broader European launch planned for the second half of 2025. Analyst discussions during the earnings call focused on market trends, with Evolus addressing concerns about market softness and the impact of its loyalty program changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.